Page 2 - Nasdaq Prds News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pardes Biosciences (NASDAQ:PRDS – Get Rating) and Decibel Therapeutics (NASDAQ:DBTX – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings. Profitability This table compares Pardes Biosciences and Decibel Therapeutics’ […]

Pardes Biosciences, Inc. (NASDAQ:PRDS – Get Rating) saw a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 2,010,000 shares, a drop of 29.2% from the March 15th total of 2,840,000 shares. Based on an average trading volume of 296,700 shares, the short-interest ratio is […]

Pardes Biosciences, Inc. (NASDAQ:PRDS – Get Rating) major shareholder Foresite Capital Opportunity M acquired 773,952 shares of the firm’s stock in a transaction that occurred on Wednesday, April 5th. The stock was acquired at an average cost of $1.50 per share, with a total value of $1,160,928.00. Following the completion of the acquisition, the insider […]

SVB Securities downgraded shares of Pardes Biosciences (NASDAQ:PRDS – Get Rating) from an outperform rating to a market perform rating in a report published on Tuesday, The Fly reports. Several other equities research analysts also recently commented on PRDS. JMP Securities reduced their target price on Pardes Biosciences from $9.00 to $5.00 and set a […]

Jefferies Financial Group lowered shares of Pardes Biosciences (NASDAQ:PRDS – Get Rating) from a buy rating to a hold rating in a research note issued to investors on Monday, The Fly reports. Jefferies Financial Group also issued estimates for Pardes Biosciences’ Q2 2023 earnings at ($0.36) EPS, Q3 2023 earnings at ($0.27) EPS, Q4 2023 […]